Global
EN CN
R&D Pipeline
Committed to New Drug Discovery on Autoimmune Disease (AID)and Cancer,Unmet Medical Needs
PipelineR&D pipeline
Product Indication PCC Pre-clinical Phase I Phase II Phase III Milestones
IRAK4 Hidradenitis suppurativa, HS PCC Pre-clinical Phase I ·AD and MAD have been completed.
·Ph1c research on AD/HS will be launched in 2025.7;
·AD’s Ph1c interim data: 2026.1
Atopic Dermatitis, AD PCC Pre-clinical Phase I
Other inflammatory diseases PCC Pre-clinical Interim data: 2026.12
STAT6 Auto-immune diseases PCC IND:2026,Q4
VAV1 Auto-immune diseases PCC IND:2027,Q2
KRAS-G12D Solid tumors PCC Pre-Clinical IND:2026,Q1
Pan-KRAS Solid tumors PCC IND:2027,Q2
IRAK4

TLRs can recognize a variety of microbial ligands, recruit MyD88, IRAK4 and IRAK1 molecules to form Myddosome complexes while IRAK4 is phosphorylated itself, and subsequently initiate the cascade of downstream events by actiating IRAK1, IKB kinase (IKK), NF-kappa B, eventually induce pro-inflammatory cytokines gene transcription and expression.

IRAK4 is the key node of IL-1 / TLR signaling pathways with the bi-function: structure and activation to initiate the inner immune system or lead to autoimmune diseases under excessive immune reaction.

The Protein Degrader molecules designed by Leadingtac are capable of both powerfully degrading IRAK4 and inhibiting IRAK4 kinase with the strong immunosuppressive effect.

Data showed that the people deficient in IRAK4 is resistant to autoimmune diseases and is totally healthy at the age of >12.

Company Mailbox
Incoming Email
Official Account